Tirzepatide and Related Peptide Therapeutics in Metabolic Regulation

Tirzepatide is a synthetic peptide with dual agonist activity at glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Structural analysis indicates that the molecule contains a modified amino acid sequence compared to GLP-1 receptor agonists such as semaglutide, which may enhance receptor binding affinity and metabolic efficacy. Preclinical studies suggest that tirzepatide modulates hepatic glucose production and pancreatic beta-cell function through coordinated activation of both GIP and GLP-1 pathways. The peptide exhibits a half-life exceeding 24 hours in murine models, supporting its potential for once-weekly administration. Clinical data indicate significant reductions in body weight and fasting plasma glucose levels when administered at therapeutic doses. Ongoing investigations explore the role of tirzepatide in related metabolic disorders including non-alcoholic fatty liver disease and type 2 diabetes management.